Trajectory of PD-L1 expression in a patient underwent neoadjuvant chemo-immunotherapy for resectable NSCLC

IF 4.5 2区医学 Q1 ONCOLOGY Lung Cancer Pub Date : 2024-08-01 DOI:10.1016/j.lungcan.2024.107900

Filippo Tommaso Gallina , Vittoria Balzano , Nicla Porciello , Riccardo Tajè , Daniele Forcella , Enrico Melis , Fabiana Letizia Cecere , Francesca Fusco , Simonetta Buglioni , Paolo Visca , Paola Nisticò , Federico Cappuzzo , Jonathan Spicer

引用次数: 0

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

可切除 NSCLC 新辅助化疗免疫疗法患者的 PD-L1 表达轨迹

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Lung Cancer 医学-呼吸系统

CiteScore

9.40

自引率

3.80%

发文量

407

审稿时长

25 days

期刊介绍： Lung Cancer is an international publication covering the clinical, translational and basic science of malignancies of the lung and chest region.Original research articles, early reports, review articles, editorials and correspondence covering the prevention, epidemiology and etiology, basic biology, pathology, clinical assessment, surgery, chemotherapy, radiotherapy, combined treatment modalities, other treatment modalities and outcomes of lung cancer are welcome.

期刊最新文献

Difference in efficacy of osimertinib between patients with EGFR-positive NSCLC with postoperative recurrence and those with de novo unresectable disease: A prospective, observational study Real-world efficacy of the dabrafenib-trametinib (D-T) combination in BRAF V600E-mutated metastatic non-small cell lung cancer (NSCLC): Results from the IFCT-2004 BLaDE cohort The efficacy of continuing osimertinib with platinum pemetrexed chemotherapy upon progression in patients with metastatic non-small cell lung cancer harboring sensitizing EGFR mutations Validation of the Lung Immune Prognostic Index in patients with untreated advanced non-small cell lung cancer: Post hoc analysis of the IMpower 130, 131 and 150 trials Impact of HA-PCI on self-reported cognitive functioning and brain metastases in small-cell lung cancer: Pooled findings of NCT01780675 and PREMER trials